Acotec Scientific Holdings Limited (HKG:6669)

Market Cap	1.83B -61.5%
Revenue (ttm)	721.55M +5.4%
Net Income	-57.98M
EPS	-0.20
Shares Out	313.39M
PE Ratio	n/a
Forward PE	11.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	447,000
Open	5.77
Previous Close	5.76
Day's Range	5.68 - 5.93
52-Week Range	5.60 - 15.32
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 955
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6669

Financial Performance

In 2025, HKG:6669's revenue was 644.63 million, an increase of 20.72% compared to the previous year's 533.99 million. Earnings were 119.18 million, an increase of 127.97%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error